AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

BerGenBio

Share Issue/Capital Change Feb 13, 2018

3555_rns_2018-02-13_37340b67-d731-4bb2-86a5-44b773a58a32.html

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

BerGenBio ASA: Exercise of employee share options and increase of capital

BerGenBio ASA: Exercise of employee share options and increase of capital

Bergen, Norway, 13 February 2018 - The Board of Directors in BerGenBio ASA (the

"Company") (OSE: BGBIO) has, to fulfil the Company's obligations under the

option agreements, resolved to increase the Company's share capital by NOK 1,000

by issuance of 10,000 new shares. The new shares shall be subscribed for by an

employee that wishes and is entitled to exercise options in accordance with the

Company's option scheme. The subscription price shall be in accordance with the

prevailing options price pursuant to the Company´s option scheme, ie NOK 24.00

per share. The shares shall be subscribed for in a separate subscription

document in the period from 13. February 2018 and up to and including 27.

February 2018.

-End-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

Tom Henrik Sundby

Finance Director, BerGenBio ASA

[email protected]

+47 477 54 415

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

Talk to a Data Expert

Have a question? We'll get back to you promptly.